PhuturdexDrug Pipeline Intelligence

Phuturdex › Diseases › Homozygous familial hypercholesterolemia

Drugs in development · updated 30 October 2026

Homozygous familial hypercholesterolemia: drugs in development

Rare diseasePrevalence 1-9 / 1 000 000 according to Orphanet · ORPHA:391665

As of 30 October 2026 there are 9 active clinical trials (recruiting or ongoing, phases I–III) on 7 drugs for homozygous familial hypercholesterolemia. 6 are experimental, that is not yet approved in the United States.

9Active trials
6Experimental drugs
2Experimental, in phase III

Summary updated every week · data as of 30 October 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.

Sign in free →

Experimental drugs

Not yet approved by the US FDA for any indication.

DrugMost advanced phaseActive trialsReference trial
ZodasiranIII2NCT07473843
VSA003III1NCT06712771
EDP167II1NCT07489209
SHR-1918II1NCT07133815
CTX310I1NCT07491172
NGGT006Early I1NCT06125847

Sorted by most advanced phase and number of active trials.

Approved drugs in new trials

Approved by the US FDA for at least one indication, not necessarily this disease, and now in active trials on it.

DrugMost advanced phaseActive trialsReference trial
InclisiranLeqvio®III2NCT05682378

Sorted by most advanced phase and number of active trials.

All 7 drugs, with the details

In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.

Open in Phuturdex →

Broader categories

Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: Wikidata; NLM MeSH term: D000090542 “Homozygous Familial Hypercholesterolemia”. Prevalence: Orphanet.

ItalianoFrançaisDeutsch